Hemomeeting

About

Hemomeeting, coordinated by Dr. Breno Gusmão, an onco-hematologist, is an initiative dedicated to the exchange of information among onco-hematology specialists from Brazil and worldwide. In a constantly evolving scientific landscape, numerous new drug options emerge annually for blood neoplasms such as lymphomas, leukemias, and multiple myeloma. The exchange of knowledge among specialists is considered essential to ensure that these advances are widely disseminated, allowing all patients access to the best available treatments.

Website

https://https://www.hemomeeting.com/

Content by Hemomeeting

Hemomeeting

23 set, 2025

QuANTUM-First: Impact of Quizartinib and Allogeneic Transplant in First Remission in FLT3-ITD–Positive AML

Acute myeloid leukemia (AML) with FLT3-ITD mutation accounts for approximately 25% of newly diagnosed cases and is associated with poor prognosis, higher relapse risk, and reduced overall survival (OS). Although intensive chemotherapy followed by allogeneic hematopoietic stem cell transplantation (allo-HCT) remains the standard of care in eligible patients, relapse risk remains high, ranging from 30% to 59% even after transplant. In this context, the second-generation selective FLT3 inhibitor

Hematology

3min